North China Pharmaceutical Co Ltd (600812) – aksjekurser og nyheter

Hvorfor har 600812 gått ned? 4,72%?

Gå mer i dybden

600812:SHA

North China Pharmaceutical Co Ltd

6,26 CNY

−4,72%

(−0,31) 1 D

16. okt., 15:00:00 GMT+8 · CNY

Alle symboler

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for 600812 …

Åpne

6,33 CNY

Høy

6,90 CNY

Lav

6,10 CNY

Snittvolum

61,12 mill.

Volum

307,76 mill.

Utbytte

0,56 %

Kvartalsvis utbytte

0,01 CNY

Første dato etter utbytte

11. juni 2026

P/E-forhold

87,26

52 u høy

6,90 CNY

52 u lav

4,11 CNY

EPS

0,07 CNY

Utestående aksjer

1,63 mrd.

Antall ansatte

10k

Åpne

6,33 CNY

Høy

6,90 CNY

Lav

6,10 CNY

Snittvolum

61,12 mill.

Volum

307,76 mill.

Utbytte

0,56 %

Kvartalsvis utbytte

0,01 CNY

Første dato etter utbytte

11. juni 2026

P/E-forhold

87,26

52 u høy

6,90 CNY

52 u lav

4,11 CNY

EPS

0,07 CNY

Utestående aksjer

1,63 mrd.

Antall ansatte

10k

Relaterte aksjer

300255

Hebei Changshan Biochemical Pharm Co Ltd

19,88 CNY

−2,02%

002603

Shijiazhuang Yiling Pharmaceuticl Co Ltd

15,06 CNY

+0,33%

300765

CSPC Innovation Pharmaceutical Co Ltd

44,10 CNY

+2,61%

600803

ENN Natural Gas Co Ltd

19,90 CNY

+0,81%

Nyhetssaker

Fra nettkilder og nyhetspartnere

Finansavisen

for 1 døgn siden

Wall Street endte opp: Statsrentenefallerkraftig

MarketBeat

for 11 minutter siden

ITHAX Acquisition Corp III (NASDAQ:ITHA) Stock Short Interest Report for September

Investing News Network

for 15 minutter siden

Kopin to Host Live YouTube "Ask Me Anything" Panel from Nasdaq MarketSite on the Future of AI Infrastructure

Simply Wall Street

for 5 minutter siden

What Has Changed For indie Semiconductor Since Its 66% Fall

Profil

North China Pharmaceutical Group Corp., is a pharmaceutical manufacturer in China. NCPC was one of the key construction projects during China's First Five-Year Plan. After five years of construction since the foundation date in June 1953, the first successful pharmaceutical production, started in June 1958. Being one of the antibiotic producers both in technology and production scale at that time, NCPC created a history of commercial production of antibiotics in China. It has 45 years of development experience. NCPC has been taking the lead in the Chinese pharmaceutical industry in key economic indexes, ranked as one of the Top500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets of the company were valued at US$2 billion, with 18,500 employees. In 2002, NCPC claimed a domestic sales revenue of US$700 million and export sales of US$100 million. Wikipedia

Om North China Pharmaceutical Co Ltd

Administrerende direktør-

Ansatte9,97k

Grunnlagt20. des. 1992

Hovedkontor-

Sektor-

Nettsted-

Alle verdier i CNY	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	2,21 mrd.	1,76 mrd.	2,15 mrd.	2,07 mrd.
Varekostnad	1,59 mrd.	1,07 mrd.	1,53 mrd.	1,54 mrd.
Direkte driftskostnader	1,59 mrd.	1,07 mrd.	1,53 mrd.	1,54 mrd.
Utgifter til forskning og utvikling	85,19 mill.	85,95 mill.	95,62 mill.	84,71 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	419,54 mill.	414,91 mill.	354,22 mill.	304,68 mill.
Driftskostnader	504,74 mill.	539,54 mill.	495,25 mill.	396,76 mill.
Totale driftskostnader	2,09 mrd.	1,61 mrd.	2,03 mrd.	1,94 mrd.
Driftsinntekter	116,01 mill.	149,57 mill.	128,11 mill.	125,58 mill.
Andre ikke-operasjonelle inntekter	−299,86k	−2,96 mill.	−10,58 mill.	6,02 mill.
EBT inkludert uvanlige elementer	73,18 mill.	70,19 mill.	66,28 mill.	57,65 mill.
EBT uten uvanlige elementer	45,54 mill.	84,31 mill.	61,80 mill.	58,08 mill.
Kostnad for inntektsskatt	23,93 mill.	24,28 mill.	16,90 mill.	16,15 mill.
Faktisk avgiftssats	32,70 %	34,59 %	25,50 %	28,02 %
Andre driftskostnader	4,82 mill.	29,30 mill.	27,82 mill.	15,57 mill.
Nettoinntekt	35,01 mill.	24,55 mill.	35,47 mill.	28,37 mill.
Netto fortjenestemargin	1,58 %	1,40 %	1,65 %	1,37 %
Resultat per aksje	-	-	-	-
Rente- og investeringsinntekter	19,41 mill.	27,71 mill.	19,26 mill.	22,40 mill.
Rentekostnader	−85,85 mill.	−85,06 mill.	−74,99 mill.	−76,52 mill.
Netto rentekostnader	−66,43 mill.	−57,35 mill.	−55,73 mill.	−54,13 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	313,14 mill.	371,92 mill.	350,45 mill.	367,38 mill.
Gevinst eller tap ved salg av eiendeler	−9,85k	−827,34k	-	−217,80k

Finance

Spør om hva som helst